Loading...

Oryzon Genomics

DB:ORN
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ORN
DB
€145M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. The last earnings update was 63 days ago. More info.


Add to Portfolio Compare Print
  • Oryzon Genomics has significant price volatility in the past 3 months.
ORN Share Price and Events
7 Day Returns
4.9%
DB:ORN
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
56.8%
DB:ORN
-10.6%
DE Biotechs
-6.2%
DE Market
ORN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Oryzon Genomics (ORN) 4.9% 2.3% 38% 56.8% - -
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • ORN outperformed the Biotechs industry which returned -10.6% over the past year.
  • ORN outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
ORN
Industry
5yr Volatility vs Market

Value

 Is Oryzon Genomics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Oryzon Genomics. This is due to cash flow or dividend data being unavailable. The share price is €3.75.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Oryzon Genomics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Oryzon Genomics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:ORN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-0.03
BME:ORY Share Price ** BME (2019-04-18) in EUR €3.78
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Oryzon Genomics.

DB:ORN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BME:ORY Share Price ÷ EPS (both in EUR)

= 3.78 ÷ -0.03

-123.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oryzon Genomics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Oryzon Genomics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Oryzon Genomics's expected growth come at a high price?
Raw Data
DB:ORN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -123.5x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-57.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Oryzon Genomics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Oryzon Genomics's assets?
Raw Data
DB:ORN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €1.17
BME:ORY Share Price * BME (2019-04-18) in EUR €3.78
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:ORN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BME:ORY Share Price ÷ Book Value per Share (both in EUR)

= 3.78 ÷ 1.17

3.22x

* Primary Listing of Oryzon Genomics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oryzon Genomics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Oryzon Genomics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Oryzon Genomics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Oryzon Genomics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-57.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Oryzon Genomics expected to grow at an attractive rate?
  • Unable to compare Oryzon Genomics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Oryzon Genomics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Oryzon Genomics's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:ORN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:ORN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -57.1%
DB:ORN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts -5.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:ORN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:ORN Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 6 -7 1
2019-12-31 6 -7 1
DB:ORN Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 7 -1 -1
2018-09-30 6 -2
2018-06-30 5 -4 -2
2018-03-31 5 -5
2017-12-31 4 -5 -5
2017-09-30 5 -5
2017-06-30 5 -4 -5
2017-03-31 5 -6
2016-12-31 5 -5 -5
2016-09-30 5 -5
2016-06-30 5 -1 -4
2016-03-31 7 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Oryzon Genomics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Oryzon Genomics's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:ORN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Oryzon Genomics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ORN Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -0.17 -0.17 -0.17 1.00
2019-12-31 -0.17 -0.17 -0.17 1.00
DB:ORN Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -0.03
2018-09-30
2018-06-30 -0.06
2018-03-31
2017-12-31 -0.16
2017-09-30
2017-06-30 -0.16
2017-03-31
2016-12-31 -0.20
2016-09-30
2016-06-30 -0.14
2016-03-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Oryzon Genomics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Oryzon Genomics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Oryzon Genomics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Oryzon Genomics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Oryzon Genomics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Oryzon Genomics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Oryzon Genomics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Oryzon Genomics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Oryzon Genomics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Oryzon Genomics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ORN Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 6.78 -1.18 3.09
2018-09-30 5.65 -1.72 3.28
2018-06-30 5.25 -1.91 3.18
2018-03-31 4.89 -4.93 3.15
2017-12-31 4.32 -5.20 3.14
2017-09-30 4.96 -5.19 3.05
2017-06-30 5.24 -5.38 3.02
2017-03-31 4.96 -6.01 2.84
2016-12-31 5.01 -5.45 2.58
2016-09-30 5.02 -4.79 2.50
2016-06-30 5.04 -3.81 2.25
2016-03-31 7.16 -0.98 2.25
2015-12-31 7.18 -0.99 2.07
2015-09-30 6.72 -0.71 1.83
2015-06-30 6.23 -0.67 1.91
2015-03-31 9.96 2.24 1.90
2014-12-31 15.54 6.65 2.03
2013-12-31 2.36 -2.16 1.15
2012-12-31 4.35 -0.61 1.71

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Oryzon Genomics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Oryzon Genomics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Oryzon Genomics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Oryzon Genomics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Oryzon Genomics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Oryzon Genomics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Oryzon Genomics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Oryzon Genomics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Oryzon Genomics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Oryzon Genomics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Oryzon Genomics Company Filings, last reported 3 months ago.

DB:ORN Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 45.13 18.23 34.32
2018-09-30 33.96 18.59 22.64
2018-06-30 34.91 20.24 26.58
2018-03-31 33.28 21.76 30.90
2017-12-31 34.43 23.40 35.16
2017-09-30 35.62 20.12 33.92
2017-06-30 36.78 21.43 37.36
2017-03-31 21.50 26.90 27.89
2016-12-31 22.73 23.20 27.27
2016-09-30 23.99 23.70 28.82
2016-06-30 24.75 22.97 29.94
2016-03-31 27.86 18.14 29.01
2015-12-31 27.59 9.07 21.73
2015-09-30
2015-06-30 13.80 10.45 4.27
2015-03-31 13.89 9.09 9.27
2014-12-31 13.89 9.09 9.27
2013-12-31 14.73 11.22 2.03
2012-12-31 16.43 9.48 2.30
  • Oryzon Genomics's level of debt (40.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (76.1% vs 40.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Oryzon Genomics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Oryzon Genomics has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 26.2% each year.
X
Financial health checks
We assess Oryzon Genomics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Oryzon Genomics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Oryzon Genomics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Oryzon Genomics dividends. Estimated to be 0% next year.
If you bought €2,000 of Oryzon Genomics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Oryzon Genomics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Oryzon Genomics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:ORN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:ORN Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Oryzon Genomics has not reported any payouts.
  • Unable to verify if Oryzon Genomics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Oryzon Genomics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Oryzon Genomics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Oryzon Genomics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Oryzon Genomics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Oryzon Genomics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Oryzon Genomics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Oryzon Genomics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Carlos Manuel Arjol
COMPENSATION €58,000
TENURE AS CEO 18.3 years
CEO Bio

Mr. Carlos Buesa Arjol Co-Founded Oryzon Genomics S.A. in 2000 and has been its Chairman and Chief Executive Officer since 2001 and serves as its President and served as its Member of Financial Advisory Board. Dr. Buesa serves as a Member of the Board of Directors at Inveready Asset Management, S.G.E.I.C., S.A. In addition, he sits on the board of other biotech companies like Neurotech Pharma and Oncnosis Pharma. He sits on the Board of various biotech companies, including Oncnosis Pharma AIE, NINFAS AIE, Neurotech SL and Geadig-Pharma AIE, among others. He is Chairman of CataloniaBIO, the association of Catalan biotech companies and he is a Board member at ASEBIO. He also sits on the Executive Committee of BioRegió de Catalunya, a regional foundation set up to foster and coordinate biotech research. Dr. Buesa has produced more than thirty papers and patents internationally, was a Member of the cellular signaling research team in the Pharmacy Faculty at the University of Barcelona, held an EU post-doctoral fellowship in the Faculty of Medicine at the University of Ghent in Belgium and later became Senior Investigator with the Flemish Institute of Biotechnology (VIB), also in Belgium. Dr. Buesa received his PhD in Biology from the University of Barcelona (UB). He has pursued various Finance and Negotiation programmes and in 2005, took the executive leadership programme (PADE) offered by the University of Navarra's IESE Business School.

CEO Compensation
  • Carlos Manuel's compensation has been consistent with company performance over the past year.
  • Carlos Manuel's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Oryzon Genomics management team in years:

4.8
Average Tenure
  • The tenure for the Oryzon Genomics management team is about average.
Management Team

Carlos Manuel Arjol

TITLE
Co-Founder
COMPENSATION
€58K
TENURE
18.3 yrs

Tamara Maes

TITLE
First Deputy President & Chief Scientific Officer
COMPENSATION
€58K

Enric Rello

TITLE
COO & CFO of Spain

Anna Baran-Djokovic

TITLE
Investor Relations Director

Emili Torrell

TITLE
Chief Business Development Officer

Neus Virgili

TITLE
Chief Intellectual Property Officer
TENURE
7.6 yrs

Cesar Molinero

TITLE
Chief Clinical Officer
TENURE
1.9 yrs

Roger Bullock

TITLE
Chief Medical Officer
TENURE
1.9 yrs

Sonia Gutierrez

TITLE
Chief of Clinical Operations

Augusto Rubio

TITLE
Secretary
Board of Directors Tenure

Average tenure and age of the Oryzon Genomics board of directors in years:

3.4
Average Tenure
58
Average Age
  • The tenure for the Oryzon Genomics board of directors is about average.
Board of Directors

Tamara Maes

TITLE
First Deputy President & Chief Scientific Officer
COMPENSATION
€58K

Isabel Aguilera Navarro

TITLE
Independent Director
COMPENSATION
€7K
AGE
58
TENURE
3.4 yrs

Carlos Manuel Arjol

TITLE
Co-Founder
COMPENSATION
€58K
TENURE
18.3 yrs

Ramón Ramón

TITLE
Independent Director
COMPENSATION
€7K
AGE
60
TENURE
3.4 yrs

Antonio Melero

TITLE
Lead Independent Director
COMPENSATION
€7K
TENURE
3.4 yrs

Josep Echarri Torres

TITLE
Director and Member of Financial Advisory Board
COMPENSATION
€6K

Isidro Abizanda

TITLE
Member of Scientific Advisory Board

Carlos López-Casas

TITLE
Member of Financial Advisory Board
AGE
58

Felipe Cardoso

TITLE
Member of Scientific Advisory Board

Leon Hooftman

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Oryzon Genomics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Oryzon Genomics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. Its clinical-stage product candidates include ORY-1001, an oncology product, which is in Phase I/IIA clinical trial for treating acute leukemia disease; and ORY-2001, a dual LSD1 and MAO-B inhibitor that is in Phase IIA clinical trial for multiple sclerosis, Alzheimer’s disease, and other neurodegenerative diseases. The company is also developing ORY-3001, a selective LSD1 inhibitor that is in preclinical stage for the treatment of non-oncological diseases; and additional programs in other cancer indications. Oryzon Genomics S.A. was founded in 2000 and is based in Barcelona, Spain.

Details
Name: Oryzon Genomics S.A.
ORN
Exchange: DB
Founded: 2000
€145,358,603
38,454,657
Website: http://www.oryzon.com
Address: Oryzon Genomics S.A.
Sant Ferran 74,
Cornellà de Llobregat,
Barcelona,
Catalonia, 08940,
Spain
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BME ORY Common Shares Bolsas y Mercados Espanoles ES EUR 14. Dec 2015
DB ORN Common Shares Deutsche Boerse AG DE EUR 14. Dec 2015
LSE 0RDB Common Shares London Stock Exchange GB EUR 14. Dec 2015
BATS-CHIXE ORYE Common Shares BATS 'Chi-X Europe' GB EUR 14. Dec 2015
Number of employees
Current staff
Staff numbers
40
Oryzon Genomics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 22:06
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/09
Last earnings filing: 2019/02/15
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.